MI-CP151 was a phase 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre review To judge numerous intravenous doses of sifalimumab, in Grownup patients with dermatomyositis or polymyositis (NCT00533091). Major trial goals have been To judge the security and tolerability of sifalimumab in dermatomyositis or polymyositis patients, while one of several exploratory https://petern877amw0.sasugawiki.com/user